Clinical Trial Update: Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and clinical tolerability of hdmASIT+TM peptides in house dust mite allergy patients has completed. The study reports safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• House Dust Mite Allergy

Drugs mentioned

• hdmASIT+TM peptides (hdmASIT+TM peptides)

Snippet

Sponsor: ASIT Biotech S.A. | Conditions: House Dust Mite Allergy | Phase 2 | Status: COMPLETED